The early-stage drug ATTR-CM for a heart condition showed potential to reverse progression of the disease. Existing drugs were designed only to slow down or stall it.
The study, which was published on Saturday in New England Journal of Medicine, found that a monoclonal NI006 antibody appeared to reduce harmful proteins buildup in heart based solely on imaging.
The drug was originally developed by Neurimmune, and it has now been licensed to Alexion – the unit for rare diseases of AstraZeneca. Given the results, researchers plan to advance the drug directly into a Phase 3 trial, said Martin Cowie, clinical vice president of cardiovascular and heart failure R&D at AstraZeneca.
Continue to STAT+ to read the full story…